NeOnc CEO buys $500K+ shares ahead of key Phase 2a brain cancer trial data

NeOnc Technologies CEO Amir Heshmatpour has invested over $500,000 in company shares recently, adding to nearly $1 million invested over the past year. This insider buying reflects strong confidence in upcoming clinical milestones, including interim data from the Phase 2a trial of NEO100 for aggressive brain cancers expected later this year. NeOnc is advancing innovative therapies aimed at overcoming the blood-brain barrier, with its NEO100 and NEO212 drugs in Phase 2 trials under FDA Fast-Track status. The CEO's purchases signal belief in the potential to improve treatment outcomes where current options fall short.